Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV). The company is also developing STimulator of INterferon Genes agonist product candidate, including SB 11285, an immunotherapeutic agent for the potential treatment of selected cancers.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone508-473-5993
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$350,000.00
Profitability
Miscellaneous
Employees29
Next Earnings Date10/24/2019 (Estimated)
OptionableNot Optionable
Spring Bank Pharmaceuticals (NASDAQ:SBPH) Frequently Asked Questions
What is Spring Bank Pharmaceuticals' stock symbol?
Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."
How were Spring Bank Pharmaceuticals' earnings last quarter?
Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) released its quarterly earnings results on Wednesday, July, 31st. The company reported ($0.28) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.56) by $0.28. View Spring Bank Pharmaceuticals' Earnings History.
When is Spring Bank Pharmaceuticals' next earnings date?
What price target have analysts set for SBPH?
5 brokers have issued 1-year price objectives for Spring Bank Pharmaceuticals' shares. Their forecasts range from $10.00 to $29.00. On average, they expect Spring Bank Pharmaceuticals' stock price to reach $20.00 in the next year. This suggests a possible upside of 596.9% from the stock's current price. View Analyst Price Targets for Spring Bank Pharmaceuticals.
What is the consensus analysts' recommendation for Spring Bank Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spring Bank Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spring Bank Pharmaceuticals.
Has Spring Bank Pharmaceuticals been receiving favorable news coverage?
Press coverage about SBPH stock has been trending somewhat negative on Thursday, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Spring Bank Pharmaceuticals earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Spring Bank Pharmaceuticals.
Are investors shorting Spring Bank Pharmaceuticals?
Spring Bank Pharmaceuticals saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 159,400 shares, a decline of 6.6% from the August 30th total of 170,700 shares. Based on an average daily trading volume, of 41,000 shares, the short-interest ratio is presently 3.9 days. Currently, 1.1% of the shares of the stock are sold short. View Spring Bank Pharmaceuticals' Current Options Chain.
Who are some of Spring Bank Pharmaceuticals' key competitors?
Some companies that are related to Spring Bank Pharmaceuticals include Xeris Pharmaceuticals (XERS), Evelo Biosciences (EVLO), Mirum Pharmaceuticals (MIRM), Kamada (KMDA), Spero Therapeutics (SPRO), GlycoMimetics (GLYC), LifeVantage (LFVN), CV Sciences (CVSI), TapImmune (MRKR), NuCana (NCNA), Affimed (AFMD), CannTrust (CTST), Acasti Pharma (ACST), Syndax Pharmaceuticals (SNDX) and Imprimis Pharmaceuticals (IMMY).
What other stocks do shareholders of Spring Bank Pharmaceuticals own?
Who are Spring Bank Pharmaceuticals' key executives?
Spring Bank Pharmaceuticals' management team includes the folowing people:
- Mr. Martin J. Driscoll, Pres, CEO & Director (Age 60)
- Dr. Radhakrishna P. Iyer, Co-Founder, Chief Scientific Officer & Director (Age 69)
- Dr. Nezam H. Afdhal, Chief Medical Officer (Age 62)
- Mr. Jonathan P. Freve CPA, CFO & Treasurer (Age 41)
- Mr. Donald Mitchell MBA, VP of Operations & Corp. Devel.
When did Spring Bank Pharmaceuticals IPO?
(SBPH) raised $14 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 1,100,000 shares at a price of $12.00-$14.00 per share. Dawson James Securities acted as the underwriter for the IPO.
How do I buy shares of Spring Bank Pharmaceuticals?
Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Spring Bank Pharmaceuticals' stock price today?
One share of SBPH stock can currently be purchased for approximately $2.87.
How big of a company is Spring Bank Pharmaceuticals?
Spring Bank Pharmaceuticals has a market capitalization of $47.24 million and generates $350,000.00 in revenue each year. The company earns $-22,850,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. Spring Bank Pharmaceuticals employs 29 workers across the globe.View Additional Information About Spring Bank Pharmaceuticals.
What is Spring Bank Pharmaceuticals' official website?
How can I contact Spring Bank Pharmaceuticals?
Spring Bank Pharmaceuticals' mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company can be reached via phone at 508-473-5993 or via email at [email protected]
MarketBeat Community Rating for Spring Bank Pharmaceuticals (NASDAQ SBPH)
MarketBeat's community ratings are surveys of what our community members think about Spring Bank Pharmaceuticals and other stocks. Vote "Outperform" if you believe SBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
